TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with plasma HCV RNA level \>10,000 IU/L for the two groups.~* Treatment-experienced patients in group 1 were those who had previously failed treatment with classical peg-IFN/RBV therapy.~* Treatment-experienced patients in group 2 were those who had previously failed treatment with SOF/RBV~Exclusion Criteria:~* coinfected with hepatitis B virus or human immunodeficiency virus infection,~* any cause of liver disease other than HCV GT4 infection;~* liver decompensation,~* hepatocellular carcinoma,~* major severe illness, such as renal failure, congestive heart failure, thyroid dysfunction, respiratory failure, autoimmune disease and poorly controlled diabetes (HbA1C \>9)~* Participants with blood picture abnormalities, such as anemia (hemoglobin concentration of 10 g/or less) and thrombocytopenia (platelet count \<50,000 cells/mm3)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SOF + RBV (Naive) (Type: ACTIVE_COMPARATOR): For treatment-naive participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
- SOF + RBV (Experienced) (Type: ACTIVE_COMPARATOR): For treatment-experienced participants, SOF was given in a dose of 400 mg/day + RBV was given orally in the morning and in the evening (total daily dose was based on body weight:\<75 kg, 1000 mg; \>75 kg, 1200 mg).
- SOF + SMV (Naive) (Type: ACTIVE_COMPARATOR): For treatment-naive participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.
- SOF + SMV (Expereined) (Type: ACTIVE_COMPARATOR): For treatment-experienced participants, SOF was given in a dose of 400 mg/day + SMV orally as a single 150 mg q.d. capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Gemcitabine,Cisplatin and Radiation Versus Cisplatin and Radiation in Cancer of the Cervix

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosed with cancer of cervix~* tumor that can be measured~* no previous treatment with chemotherapy or radiation for this cancer~* Karnofsky Performance Status Score \>=70~* able to give written consent~* willing and able to participate in the study, both during the active treatment and the follow-up period.~Exclusion Criteria:~* impairment such as hearing loss from prior cisplatin therapy~* damage to nerves such as being unable to distinguish hot and cold to touch~* used other experimental medication in past 30 days~* lab test results are not within the limits required for this study~* pregnancy or breast-feeding or possibility of becoming pregnant during this study and not using an approved method of birth control.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Gemcitabine 125 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week~Two week rest period with no chemotherapy or radiation~Cisplatin, 50 mg/m2, intravenous (IV), day 1 of 21 day cycle for two 21-day cycles and Gemcitabine, 1000 mg/m2, day 1 and day 8 for two 21 day cycles
- 2 (Type: ACTIVE_COMPARATOR): Cisplatin, 40 mg/m2, once weekly (QW), intravenous (IV), 6 weeks and Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks~Brachytherapy, 30-35 Gy over 1 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Steroid Injection Treatment of Carpal Tunnel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Primary, idiopathic CTS~* Age 18-70 years, either gender~* Symptom duration of at least 3 months and inadequate response to wrist splint~* Symptoms of classic or probable CTS according to the diagnostic criteria in Katz hand diagram~* Nerve conduction studies showing median neuropathy at the wrist and no other abnormalities or, in the absence of abnormal nerve conduction study results, 2 surgeons should independently diagnose the patient with CTS.~* Scheduled for carpal tunnel release (ie, symptom severity indicating need for surgery)exclusion criteria~Exclusion Criteria:~* Previous steroid injection for CTS in the same wrist~* Inflammatory joint disease, diabetes mellitus· Vibration-induced neuropathy, polyneuropathy~* Pregnancy~* Trauma to the affected hand in the previous year~* Previous CTS surgery in the affected hand~* Inability to complete questionnaires due to language problem or cognitive disorder~* Severe medical illness~* Known abuse of drugs and/or alcohol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): None
- B (Type: ACTIVE_COMPARATOR): None
- C (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Eligible participants were premenopausal women with SLE~* Older than 18 years~* Attending the outpatient Rheumatology Clinic at three Mexico City community tertiary care hospitals~Exclusion Criteria:~* menopause~* diabetes~* thyroid dysfunction~* neurological~* hepatic~* renal or liver disease~* personal history of high blood pressure~* CHD (coronary heart disease)~* cerebrovascular events~* chronic or acute infections~* malignancy~* nor history of chronic drugs or alcohol abuse~* smoking~* pregnancy or breast-feeding~* intake of hormones or lipid-regulating drugs

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- sugar pill (Type: PLACEBO_COMPARATOR): tablet similar to comparator
- pioglitazone (Type: ACTIVE_COMPARATOR): 30 mg tablets QD (taken once daily)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ezopiclone Improves the Quality of Overnight Polysomnography

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All adult patients aged 18-65, evaluated by a sleep medicine provider in the Walter Reed Army Medical Center Sleep Disorders Clinic, who are referred for PSG for suspected Obstructive Sleep Apnea Syndrome~Exclusion Criteria:~* Pregnancy~* Liver dysfunction or history of EtOH abuse~* Concomitant use of benzodiazepines, narcotics or ketozonazole~* Decompensated CHF~* CVA within 3 months~* Uncontrolled psychiatric disorders~* Patients \< 18 years old~* Patients over 65

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- PSG (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The SCCS Polypill Pilot Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled at the SCCS site in Mobile, Alabama, obtain care at Franklin Primary Health Center, or live in the surrounding area.~* Aged 45-75 years~* Baseline systolic blood pressure ≥120 mm Hg. In this open-label trial, the study physicians are permitted to prescribe any additional medication deemed appropriate to achieve blood pressure control.~Exclusion Criteria:~* History of coronary heart disease or stroke~* History of cancer, except for basal cell skin cancer~* History of liver disease, not including chronic, clinically-stable hepatitis~* Laboratory evidence of hepatic dysfunction (an alanine aminotransferase level more than two times the upper limit of the normal range)~* Known renal disease, estimated creatinine clearance \< 60~* Current use of more than 2 anti-hypertensive medications~* LDL cholesterol ≥190 mg/dl~* Insulin-dependent diabetes~* Known intolerance to any of the components of the polypill~* Potassium \<3.4 or \>5.5 mEq/L~* Use of medications that interact with statins, including those affecting the cytochrome P450 system~* Current use of diuretics for indications other than hypertension~* Comorbidities that might be expected to limit lifespan during the 12-month follow-up period~* Inability to provide consent.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Subjects in this arm will not receive any investigational medications. They will remain on the same care that they are use to receiving.
- Polypill (Type: EXPERIMENTAL): The study medication will be a fixed-dose combination pill (polypill) containing: Atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg.~Polypill will be taken once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigation the Safety and Efficacy of The Antileukotriene Agents, Montelukast, as Adjuvant Therapy in Obese Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- type 2 diabetic patients who had body mass index (BMI) ≥ 30 kg/m2 , were treated with metformin alone and had ages ranging from 18 to 60 years.~Exclusion Criteria:~* patients who had any other inflammatory disease~* patients with cardiovascular,~* patients with asthma~* patients with severe hepatic~* patients with renal disease,~* patients with epilepsy~* pregnant or lactating females.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): 50 patients will receive metformin up to 2000mg/daily (Control group)
- Montelukast group (Type: EXPERIMENTAL): 50 patients will receive a combination of metformin up to 2000 mg/daily and montelukast (10 mg /day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* HCV RNA ≥ 10\^4 IU/mL at screening~* HCV genotype 1, 2, 3, 4, 5, 6~* Cirrhosis determination, a fibroscan or liver biopsy may be required~* HIV-1 infection~* Use of protocol specified method(s) of contraception~* Screening laboratory values within defined thresholds~Key Exclusion Criteria:~* Clinically-significant illness (other than HCV or HIV) or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol~* Current or prior history of clinical hepatic decompensation, hepatocellular carcinoma (HCC) or other malignancy (with the exception of certain resolved skin cancers)~* Screening ECG with clinically significant abnormalities~* Pregnant or nursing female or male with pregnant female partner~* Infection with hepatitis B virus (HBV)~* Use of any prohibited concomitant medications as described in the protocol~* Chronic use of systemically administered immunosuppressive agents~NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): Participants will receive SOF/VEL for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mobile Diabetes Management

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetic \[patient\]~* A1c equal to or greater than 7.5 \[patient\]~* 18-64 years of age at time of recruitment \[patient\]~* Access to the internet (does not need to be at their home, elsewhere is fine e.g. work) \[patient\]~* E-mail account \[patient\]~* Must speak English \[patient\]~Exclusion Criteria:~* No insulin pump \[patient\]~* No current alcohol or drug abuse- must be sober 1 year \[patient\]~* Not currently pregnant \[patient\]~* No terminal diagnosis \[patient\]~* No dementia or Alzheimer's \[patient\]~* No active chemotherapy \[patient\]~* No significant hearing impairment \[patient\]~* Poorly corrected vision that would impede use of phone \[patient\]~* No mute or aphasia \[patient\]~* No diagnosis of schizophrenia, bipolar disorder, or major psychosis \[patient\]~* No Medicaid or Medicare~* No uninsured

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Usual Care (Type: NO_INTERVENTION): Provider-driven care, based in office, no special diabetes management; Patient self-monitoring of blood glucose (SMBG)
- Group 2: patient intervention (Type: ACTIVE_COMPARATOR): Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback
- Group 3: patient-physician intervention (Type: ACTIVE_COMPARATOR): Home diabetes monitoring by patient using mobile phone to communicate and receive feedback; Physician can access unanalyzed information from the patient's electronic logbook
- Group 4: data analyzed intervention (Type: ACTIVE_COMPARATOR): Home diabetes monitoring by patient using mobile phone to communicate information and receive feedback; Physician can access raw and analyzed patient data; Physician receives report summary and treatment recommendations

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Elagolix in Women With Endometriosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be female, aged 18 to 49 years, inclusive.~* Have moderate to severe pelvic pain due to endometriosis.~* Have a history of regular menstrual cycles.~* Have been surgically (laparoscopy or laparotomy) diagnosed with endometriosis within 8 years of the start of screening.~* Have a Body Mass Index (BMI) of 18 to 36 kg/m², inclusive.~* Agree to use two forms of non-hormonal contraception during the study.~Exclusion Criteria:~* Are currently receiving gonadotropin-releasing hormone (GnRH) agonist, a GnRH antagonist other than NBI-56418, or danazol or have received any of these agents within 6 months of the start of screening.~* Are currently receiving subcutaneous medroxyprogesterone acetate (DMPA-SC) or intramuscular medroxyprogesterone acetate (DMPA-IM) or have received any of these agents within 3 months of the start of screening.~* Are currently using hormonal contraception or other forms of hormonal therapy or received such treatment within the last month.~* Have had surgery for endometriosis within the last month.~* Have had a hysterectomy or bilateral oophorectomy.~* Are using systemic steroids on a chronic or regular basis within 3 months.~* Have uterine fibroids ≥ 3 cm in diameter.~* Have pelvic pain that is not caused by endometriosis.~* Have unstable medical condition or chronic disease.~* Have been pregnant within the last six months.~* Currently breast feeding.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: f

Study Arms:
- Elagolix 150 mg (Type: EXPERIMENTAL): Participants received 150 mg elagolix orally once a day for 8 weeks during the double-blind treatment period and continued to receive 150 mg elagolix for 16 additional weeks during the open-label treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo orally once a day for 8 weeks during the double-blind treatment period and switched to receive 150 mg elagolix for 16 weeks during the open-label treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all types of chronic hand eczema, lasting for at least 6 months since initial diagnosis~* rated as severe by the physician~* unresponsive to highly potent topical corticosteroids, such as clobetasol~Exclusion Criteria:~* patients whose disease is adequately controlled by standard non-medicated therapy, including potent topical steroids, skin moisturizers, and avoidance of allergens and irritants~* patients with known allergens and irritants, who have not made a reasonable effort to avoid the substances~* patients with psoriasis lesions~* active fungal, bacterial or viral infections of the hands~* female patients who are pregnant or breastfeeding~* female patients of childbearing potential who cannot use or will not commit to use two effective methods of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Alitretinoin (Type: EXPERIMENTAL): Patients will receive alitretinoin 30mg capsule for up to 24 weeks
- Placebo (Type: EXPERIMENTAL): Patients will receive placebo 30mg capsule for up to 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects between 18 and 45 years of age at the time of pregnancy under consideration for the study, who deliver in the study centre.~* Residents of the study area~* Subjects who were compliant with the routine antenatal care including at least one ultrasound assessment report early in the pregnancy.~* Subjects with the complete and relevant medical records available.~Inclusion criteria for the Exposed cohort:~* Subjects who received one dose of Refortrix vaccine in the recommended time period between 27 and 36 completed weeks of pregnancy (or as late as 20 days before delivery due date) as part of the maternal immunization program in Brazil, and according to the program recommendations from May 2015 onwards.~* Subjects with appropriate vaccination records.~Inclusion criteria for the Unexposed cohort:~* Subjects who had delivered in the same hospital (study centre) before 01 September 2014 (September 2012-August 2014) and who did not receive Tdap vaccination during pregnancy to the best knowledge of the investigator.~Exclusion Criteria:~* Subjects who have been transferred to other specialised centres, where their medical records would be inaccessible for the study (private clinics, psychiatric or prison hospitals, other state hospitals, etc).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Exposed cohort (Type: None): Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) from May 2015 and who received one dose of Refortrix during 27 to 36 weeks of pregnancy (or as late as 20 days before delivery due date).
- Unexposed cohort (Type: None): Women, 18-45 years of age at the time of pregnancy, who delivered in the hospital (study centre) before implementation of the maternal immunization program in Brazil in September 2014 and who did not receive Tdap vaccination during pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete